What happened with ZSTK today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ZeroStack Corp. sells pharmaceutical goods and medical products through Phatebo, its wholly owned German wholesaler. Phatebo imports and exports products to customers mainly in Europe, earning a margin when selling prices exceed purchase and distribution costs. This business supplies all current revenue, with sales concentrated primarily in Germany. Two unnamed customers each account for a substantial share of sales, making their purchases important to the business.
Alongside distribution, ZeroStack invests its own capital in digital assets, with a strategy centered on accumulating and holding 0G tokens for the long term. It seeks to grow its holdings through staking—putting digital assets to work to earn rewards—but the digital-assets segment has not yet generated revenue. Its asset value depends heavily on 0G’s market price rather than pharmaceutical sales.
ZeroStack cannot sell the 0G tokens received under its Zero Gravity convertible note, or their staking rewards, without Zero Gravity’s written consent. Uncertain securities-law treatment could also restrict its ability to hold or transfer tokens. The company intends to avoid investment-company status, which may require limiting investments or changing operations.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Solana Company and ZeroStack both buy and hold digital assets and earn rewards by staking them, so crypto-market conditions matter to both—but Solana Company centers on SOL and ZeroStack on 0G. Watch its SOL staking income and treasury financing, not SOL prices as a direct measure of ZeroStack’s holdings.
Cencora competes with ZeroStack’s Phatebo in supplying medicines to healthcare customers, with both businesses focused primarily on Europe. Its international pharmaceutical wholesale results offer a closer comparison for Phatebo than its U.S. distribution business.
Cosmos Holdings Inc. overlaps with ZeroStack’s Phatebo in selling and distributing medicines, but also develops and manufactures healthcare products. Its generic-drug sales are the relevant comparison; drug-development news concerns activities beyond Phatebo’s wholesale business.
McKesson and ZeroStack’s Phatebo both make money distributing medicines, so drug volumes, purchasing costs and distribution margins matter to both, rather than mainly competition for the same local buyers. McKesson serves U.S. and Canadian customers, including pharmacies and hospitals, while Phatebo focuses primarily on Europe; watch McKesson’s North American pharmaceutical business for those pressures.
Cardinal Health and ZeroStack’s Phatebo both depend on delivering medicines profitably through low-margin supply chains, although Cardinal’s pharmaceutical distribution is predominantly U.S.-based and Phatebo’s is Europe-centered. Watch Cardinal’s pharmaceutical distribution margins on sales to customers such as hospitals and pharmacies: lower margins at Phatebo drove ZeroStack’s gross margin down to 5% in 2025 from 6% in 2024.
Cencora, Inc. earningsCOR
Cencora’s international medicine wholesale business is a closer match for Phatebo, so its report can show the demand and competitive conditions facing European wholesalers.
Focus on Cencora’s international pharmaceutical wholesale business, not its U.S. distribution as a direct proxy for Phatebo. Strength there would suggest the demand and competitive backdrop for wholesalers is supportive, a favorable sign for Phatebo’s sales environment. Weakness would point to a tougher backdrop in the shared European market, but would not establish Phatebo’s own results.
Cardinal Health, Inc. earningsCAH
Cardinal Health also runs a low-margin pharmaceutical distribution business, so its distribution margins offer a read on the cost and spread pressures Phatebo faces.
Read Cardinal Health’s pharmaceutical distribution margin alongside its sales. A stable or improving margin would suggest distributors can still cover purchasing and service costs from sales, a favorable sign for Phatebo’s thin-margin model. A falling margin would signal spread pressure and a similar risk for Phatebo, though U.S. results do not directly represent Europe.
ZeroStack Corp. earningsThis company
ZeroStack Corp. earns a thin margin distributing medicines, while its 0G holdings can swing reported earnings; this report will show how each is affecting the business.
Read Phatebo’s medicine sales and gross margin alongside the gain or loss from changes in 0G’s fair value. Improving sales and margin with a smaller 0G-related loss would mean the distribution business is contributing more as the treasury drag eases. A pressured margin and a larger 0G-related loss would show how little cushion the core business has against swings in ZeroStack’s concentrated 0G holdings.
Solana Company earningsHSDT
Solana Company also holds and stakes digital assets; its staking income and financing offer a reference for this treasury model, but do not measure ZeroStack’s 0G performance.
Watch Solana Company’s staking income and financing, not SOL’s price as a proxy for ZeroStack’s 0G. Steady staking income and available financing would show that this kind of treasury can obtain some resources beyond token holdings; weak income or constrained financing would suggest limited cushion for ZeroStack’s 0G-focused treasury.
